523 related articles for article (PubMed ID: 21764800)
21. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
Ong LC; Jin Y; Song IC; Yu S; Zhang K; Chow PK
Acta Radiol; 2008 Dec; 49(10):1145-53. PubMed ID: 18979289
[TBL] [Abstract][Full Text] [Related]
22. FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.
Li Z; Graf N; Herrmann K; Jünger A; Aichler M; Feuchtinger A; Baumgart A; Walch A; Peschel C; Schwaiger M; Buck A; Keller U; Dechow T
Cancer Res; 2012 Oct; 72(19):5014-24. PubMed ID: 22875026
[TBL] [Abstract][Full Text] [Related]
23. Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts.
Tsuji AB; Sogawa C; Sugyo A; Sudo H; Toyohara J; Koizumi M; Abe M; Hino O; Harada YN; Furukawa T; Suzuki K; Saga T
Nucl Med Biol; 2009 May; 36(4):379-88. PubMed ID: 19423005
[TBL] [Abstract][Full Text] [Related]
24. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
[TBL] [Abstract][Full Text] [Related]
25. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
[TBL] [Abstract][Full Text] [Related]
26. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
[TBL] [Abstract][Full Text] [Related]
27. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
[TBL] [Abstract][Full Text] [Related]
28. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
29. Preclinical evaluation of a novel c-Met inhibitor in a gastric cancer xenograft model using small animal PET.
Wiehr S; von Ahsen O; Röse L; Mueller A; Mannheim JG; Honndorf V; Kukuk D; Reischl G; Pichler BJ
Mol Imaging Biol; 2013 Apr; 15(2):203-11. PubMed ID: 22864665
[TBL] [Abstract][Full Text] [Related]
30. Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Leimgruber A; Möller A; Everitt SJ; Chabrot M; Ball DL; Solomon B; MacManus M; Hicks RJ
J Nucl Med; 2014 Jul; 55(7):1075-80. PubMed ID: 24868108
[TBL] [Abstract][Full Text] [Related]
31. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with 18F-FDG and 18F-FLT.
Zhao S; Kuge Y; Kohanawa M; Takahashi T; Zhao Y; Yi M; Kanegae K; Seki K; Tamaki N
J Nucl Med; 2008 Jan; 49(1):135-41. PubMed ID: 18077525
[TBL] [Abstract][Full Text] [Related]
33. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
34. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.
Jensen MM; Erichsen KD; Björkling F; Madsen J; Jensen PB; Højgaard L; Sehested M; Kjær A
PLoS One; 2010 Sep; 5(9):e12965. PubMed ID: 20885974
[TBL] [Abstract][Full Text] [Related]
35. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
36. [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.
Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
BMC Cancer; 2013 Apr; 13():168. PubMed ID: 23548101
[TBL] [Abstract][Full Text] [Related]
37. [18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner.
Graf N; Herrmann K; Numberger B; Zwisler D; Aichler M; Feuchtinger A; Schuster T; Wester HJ; Senekowitsch-Schmidtke R; Peschel C; Schwaiger M; Keller U; Dechow T; Buck AK
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):34-43. PubMed ID: 23053327
[TBL] [Abstract][Full Text] [Related]
38. Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors.
Goggi JL; Bejot R; Moonshi SS; Bhakoo KK
J Nucl Med; 2013 Sep; 54(9):1630-6. PubMed ID: 23907757
[TBL] [Abstract][Full Text] [Related]
39. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
Katz SI; Zhou L; Ferrara TA; Wang W; Mayes PA; Smith CD; El-Deiry WS
Int J Oncol; 2011 Jul; 39(1):91-100. PubMed ID: 21537838
[TBL] [Abstract][Full Text] [Related]
40. Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1α activation.
Jung KH; Lee JH; Thien Quach CH; Paik JY; Oh H; Park JW; Lee EJ; Moon SH; Lee KH
J Nucl Med; 2013 Dec; 54(12):2161-7. PubMed ID: 24221993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]